Latest from Le Devoir
Le Devoir
7 days ago
- Business
- Le Devoir
Syensqo Appoints Two New Board Members
Syensqo Appoints Two New Board Members Brussels, Belgium – July 17, 2025 - 17:30 CEST New Directors Bring Industry, Innovation and Leadership Experience to Advance Syensqo's Evolution to a Specialty Chemicals Company SYENSQO SA ('Syensqo' or 'the Company') is pleased to announce the appointment of Dr. Cynthia Arnold and Augusto Di Donfrancesco as new members of its Board of Directors, effective July 17, 2025. They replace Matti Lievonen and Nadine Leslie who are stepping down from the Board to pursue other opportunities. Dr. Cynthia Arnold brings more than 30 years of global leadership experience in technology and innovation within the materials and chemicals sectors. She previously served as Chief Technology Officer at Valspar Corporation and held senior roles at Sun Chemical, Eastman Chemical and General Electric. With extensive public company board experience, Dr. Arnold currently serves as an independent director on the boards of Cabot Corporation, Milliken & Company and Fluence Energy. She holds a PhD in Materials Science and Engineering from Virginia Polytechnic Institute and an MBA from the University of California,Berkeley. Augusto Di Donfrancesco held key leadership roles in research & innovation, operations and transformation during a more than 35-year career at Solvay. As President of Solvay's Specialty Polymers Global Business Unit, he led a period of significant organic growth, doubling net sales through customer-centric innovation. He was also a member of the Solvay Executive Leadership Team where he led group-wide strategic programs. Mr. Di Donfrancesco's deep sector knowledge and track record in operational excellence and capital allocation will further reinforce Syensqo's ongoing growth and transformation objectives. Mr. Di Donfrancesco holds a bachelor's degree in chemical engineering from Pisa University. Rosemary Thorne, Chair of the Board of Directors, said, 'On behalf of the Board, I would like to express our gratitude to Matti and Nadine for their contributions to the Board during Syensqo's formative period as an independent public company. As part of our Board succession planning, we are focused on maintaining the right mix of skills and expertise and are thrilled to welcome Cynthia and Augusto, who are proven leaders of the highest caliber and are poised to contribute their significant leadership, technology, innovation and operational experience to the Board. We look forward to benefiting from their respective knowledge and insights as we continue to focus on delivering shareholder value.' 'We are delighted to welcome Cynthia and Augusto to our Board,' said Dr. Ilham Kadri, Chief Executive Officer of Syensqo. 'Their perspectives will be invaluable as we continue to prioritize innovation and operational excellence to capitalize on the meaningful long-term growth and value creation opportunities ahead. I look forward to working with them.' Dr. Arnold said, 'Syensqo's commitment to scientific excellence and sustainability resonates deeply with me. I am excited to contribute to the Board's work to advance innovation and operational performance, and to help shape the Company's continued success in a rapidly evolving global landscape.' 'I am honored to join Syensqo's Board during this important period in the Company's evolution to a Specialty Chemicals Company' said Mr. Di Donfrancesco. 'Having spent my career driving transformation, innovation and growth within the specialty chemicals sector, I look forward to working with my fellow directors and the management team to help accelerate growth and unleash Syensqo's potential.' Contacts Safe harbor This press release may contain forward-looking information. Forward-looking statements describe expectations, plans, strategies, goals, future events or intentions. The achievement of forward-looking statements contained in this press release is subject to risks and uncertainties relating to a number of factors, including general economic factors, interest rate and foreign currency exchange rate fluctuations, changing market conditions, product competition, the nature of product development, impact of acquisitions and divestitures, restructurings, products withdrawals, regulatory approval processes, all-in scenario of R&I projects and other unusual items. Consequently, actual results or future events may differ materially from those expressed or implied by such forward-looking statements. Should known or unknown risks or uncertainties materialize, or should our assumptions prove inaccurate, actual results could vary materially from those anticipated. The Company undertakes no obligation to publicly update or revise any forward-looking statements. About Syensqo Syensqo is a science company developing groundbreaking solutions that enhance the way we live, work, travel and play. Inspired by the scientific councils which Ernest Solvay initiated in 1911, we bring great minds together to push the limits of science and innovation for the benefit of our customers, with a diverse, global team of more than 13,000 associates. Our solutions contribute to safer, cleaner, and more sustainable products found in homes, food and consumer goods, planes, cars, batteries, smart devices and health care applications. Our innovation power enables us to deliver on the ambition of a circular economy and explore breakthrough technologies that advance humanity. Useful links
Le Devoir
7 days ago
- Business
- Le Devoir
EssilorLuxottica: Second-Quarter and First-Half 2025 Results Conference Call Invitation
Second-Quarter and First-Half 2025 Results Conference Call Invitation Mr FRANCESCO MILLERI, Chairman and Chief Executive Officer, Mr PAUL DU SAILLANT, Deputy Chief Executive Officer, Mr STEFANO GRASSI, Chief Financial Officer, and Mr GIORGIO IANNELLA, Head of Investor Relations, have the pleasure of inviting you to our Second-Quarter and First-Half 2025 Results Conference Call on: Monday, July 28, 2025, at 6:30 pm CEST Dial-in telephone access: If you wish to dial into the conference call, please pre-register at the following link to receive the personal credentials (Dial-in numbers, Conference ID and User ID): If you encounter any issue in the pre-registration phase you may contact ir@ providing your name and surname and the name of your company. Live webcast: You can watch the presentation at the following link: The press release will be published at 6:00 pm CEST on the same day and the presentation slides will be made available prior to the call. Both can be found on Pièce jointe
Le Devoir
07-07-2025
- Business
- Le Devoir
Inventiva receives $10 million milestone payment from CTTQ
Daix (France), New York City (New York, United States), July 7, 2025 – Inventiva (Euronext Paris and Nasdaq: IVA) ('Inventiva' or the 'Company'), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated steatohepatitis ('MASH'), today announced the receipt of a $10 million milestone payment from Chia Tai-Tianqing Pharmaceutical Group Co., Ltd ('CTTQ'), a subsidiary of Sino Biopharm. This milestone payment follows the successful settlement of the second tranche of €115.6 million 1 in gross proceeds (net proceeds of €108.5 million) of the previously announced structured financing of up to €348 million 2 (the 'Structured Financing'). In September 2022, Inventiva entered into a licensing and collaboration agreement with CTTQ (as amended on October 11, 2024, the 'CTTQ License Agreement') to develop and commercialize lanifibranor, Inventiva's proprietary compound, for the treatment of MASH and potentially other metabolic diseases in Mainland China, Hong Kong Special Administrative Region, Macau Special Administrative Region and Taiwan. Under the CTTQ License Agreement, Inventiva is eligible to receive up to an additional $265 million of clinical, regulatory and commercial milestone payments, as well as royalties in the low single digits on annual net sales of lanifibranor, if approved. Based on the results from the Phase 2b NATIVE clinical trial, lanifibranor was granted Breakthrough Therapy Designation for MASH by the U.S. Food and Drug Administration in October 2020 and by the Chinese National Medical Products Administration (NMPA) in December 2023. This designation could potentially accelerate the development and regulatory review of drug candidates for serious or life-threatening conditions. CTTQ joined Inventiva's ongoing NATiV3 pivotal Phase 3 clinical trial, which includes over 60 sites across mainland China. Furthermore, CTTQ has completed a Phase I bridging study and confirmed no significant ethnic differences, thereby paving the way to seek regulatory approval in China based on the results of the NATiV3 trial. About Inventiva Inventiva is a clinical-stage biopharmaceutical company focused on the research and development of oral small molecule therapies for the treatment of patients with MASH. The Company is currently evaluating lanifibranor, a novel pan-PPAR agonist, in the NATiV3 pivotal Phase 3 clinical trial for the treatment of adult patients with MASH, a common and progressive chronic liver disease. Inventiva is a public company listed on compartment B of the regulated market of Euronext Paris (ticker: IVA, ISIN: FR0013233012) and on the Nasdaq Global Market in the United States (ticker: IVA). Contacts Important Notice This press release contains 'forward-looking statements' within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this press release are forward-looking statements. These statements include, but are not limited to, Inventiva's expectations regarding the CTTQ License Agreement, including the potential receipt of milestones payments and royalties thereunder and the timing thereof, forecasts and estimates with respect to Inventiva's NATiV3 Phase 3 clinical trial with lanifibranor in patients with MASH, including design, duration, timing, costs, and the results and timing thereof, and regulatory matters with respect thereto, insights and impacts that may be gathered from clinical trials, the potential therapeutic benefits of Inventiva's product candidates, potential regulatory submissions, approvals and commercialization, the expected benefit of having received Breakthrough Therapy Designation, including its impact on the development and review timeline of Inventiva's product candidates and approvals, expectations with respect to clinical development and potential commercialization by CTTQ, Inventiva's pipeline development plans, future activities, expectations, plans, growth and prospectsof Inventiva. Certain of these statements, forecasts and estimates can be recognized by the use of words such as, without limitation, 'believes', 'anticipates', 'expects', 'intends', 'plans', 'seeks', 'estimates', 'may', 'will', 'would', 'could', 'might', 'should', 'designed', 'hopefully', 'target', 'potential', 'possible', 'aim', and 'continue' and similar expressions. Such statements are not historical facts but rather are statements of future expectations and other forward-looking statements that are based on management's beliefs. These statements reflect such views and assumptions prevailing as of the date of the statements and involve known and unknown risks and uncertainties that could cause future results, performance or future events to differ materially from those expressed or implied in such statements. Actual events are difficult to predict and may depend upon factors that are beyond Inventiva's control. There can be no guarantees with respect to product candidates that the clinical trial results will be available on their anticipated timeline, that future clinical trials will be initiated as anticipated, that product candidates will receive the necessary regulatory approvals, or that any of the anticipated milestones by Inventiva or its partners will be reached on their expected timeline, or at all. Future results may turn out to be materially different from the anticipated future results, performance or achievements expressed or implied by such statements, forecasts and estimates, due to a number of factors, including that interim data or data from any interim analysis of ongoing clinical trials may not be predictive of future trial results, the recommendation of the DMC may not be indicative of a potential marketing approval, Inventiva cannot provide assurance on the impacts of the Suspected Unexpected Serious Adverse Reaction on the results or timing of the NATiV3 trial or regulatory matters with respect thereto, that Inventiva is a clinical-stage company with no approved products and no historical product revenues, Inventiva has incurred significant losses since inception, Inventiva has never generated any revenue from product sales, Inventiva will require additional capital to finance its operations, in the absence of which, Inventiva may be required to significantly curtail, delay or discontinue one or more of its research or development programs or be unable to expand its operations or otherwise capitalize on its business opportunities and may be unable to continue as a going concern,Inventiva's ability to obtain financing and to enter into potential transactions, Inventiva's future success is dependent on the successful clinical development, regulatory approval and subsequent commercialization of lanifibranor, preclinical studies or earlier clinical trials are not necessarily predictive of future results and the results of Inventiva's and its partners' clinical trials may not support Inventiva's and its partners' product candidate claims, Inventiva's expectations with respect to its clinical trials may prove to be wrong and regulatory authorities may require additional holds and/or amendments to Inventiva's clinical trials, Inventiva's expectations with respect to the clinical development plan for lanifibranor for the treatment of MASH may not be realized and may not support the approval of a New Drug Application, Inventiva's ability to identify additional products or product candidates with significant commercial potential, Inventiva's expectations with respect to its pipeline prioritization plan and related workforce reduction, including potential benefits, expenses and consequences relating thereto, Inventiva's ability to execute on its commercialization, marketing and manufacturing capabilities and strategy, Inventiva's ability to successfully cooperate with existing partners or enter into new partnerships, and to fulfill its obligations under any agreements entered into in connection with such partnerships, the benefits of its existing and future partnerships on the clinical development, regulatory approvals and, if approved, commercialization of its product candidates, and the achievement of milestones thereunder and the timing thereof, Inventiva and its partners may encounter substantial delays beyond expectations in their clinical trials or fail to demonstrate safety and efficacy to the satisfaction of applicable regulatory authorities, the ability of Inventivaand its partners to recruit and retain patients in clinical studies, enrollment and retention of patients in clinical trials is an expensive and time-consuming process and could be made more difficult or rendered impossible by multiple factors outside Inventiva's and its partners' control, Inventiva's product candidates may cause adverse drug reactions or have other properties that could delay or prevent their regulatory approval, or limit their commercial potential, Inventiva faces substantial competition and Inventiva's and its partners' business, and preclinical studies and clinical development programs and timelines, its financial condition and results of operations could be materially and adversely affected by changes in laws and regulations, unfavorable conditions in its industry, geopolitical events, such as the conflict between Russia and Ukraine and related sanctions, the conflict in the Middle East and the related risk of a larger conflict, health epidemics, and macroeconomic conditions, including developments in international trade policies, global inflation, financial and credit market fluctuations, tariffs and other trade barriers, international trade relations, political turmoil, and natural catastrophes, uncertain financial markets and disruptions in banking systems. Given these risks and uncertainties, no representations are made as to the accuracy or fairness of such forward-looking statements, forecasts and estimates. Furthermore, forward-looking statements, forecasts and estimates only speak as of the date of this press release. Readers are cautioned not to place undue reliance on any of these forward-looking statements. Please refer to the Universal Registration Document for the year ended December 31, 2024 filed with the Autorité des Marchés Financiers on April 15, 2025, and the Annual Report on Form 20-F for the year ended December 31, 2024, filed with the Securities and Exchange Commission (the 'SEC') on April 15, 2025 for other risks and uncertainties affecting Inventiva, including those described under the caption 'Risk Factors' and in future filings with the SEC. Other risks and uncertainties of which Inventiva is not currently aware may also affect its forward-looking statements and may cause actual results and the timing of events to differ materially from those anticipated. All information in this press release is as of the date of the release. Except as required by law, Inventiva has no intention and is under no obligation to update or review the forward-looking statements referred to above. Consequently, Inventiva accepts no liability for any consequences arising from the use of any of the above statements. 1 Cf. press release dated May 5, 2025 2 Cf. press release dated October 14, 2024 Pièce jointe Inventiva - CP - CTTQ Milestone - FR - 07 07 2025
Le Devoir
11-06-2025
- Business
- Le Devoir
Fnac Darty met en œuvre un programme de rachat
Ivry-sur-Seine, France, June 11, 2025 – 7:30AM Fnac Darty implements a share buyback program Fnac Darty has announced the implementation of a share buyback program for a total of 600,000 shares as part of the share buyback program authorised at the Shareholders' Meeting of May 28, 2025. A first buyback mandate has been granted to investment services provider NATIXIS for a maximum amount of €5 million. This initiative follows on from the Board of Directors' decision to allow share buyback in the proportion necessary to offset the dilution caused by the vesting of free shares allocated to the Group's employees and Corporate Officers. CONTACTS ANALYSTS/INVESTORS Domitille Vielle — Head of Investor Relations — — +33 (0)6 03 86 05 02 Laura Parisot — Investor Relations Manager — — +33 (0)6 64 74 27 18 PRESS Bénédicte Debusschere – Head of Media Relations and Influence – – +33 (0)6 48 56 70 71 Pièce jointe 20250611_Fnac_Darty_CP_SBB_vFR vDef
